5
Total investments
1
Early stage
0
Mid stage
3
Late stage
12y
Years active
Portfolio
5 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Apr 2026
At Epistemic AI we are building the next generation of tools to accelerate biomedical research with AI and NLP.
We are a group of senior scientists and engineers from the likes of Google, New York University, Stanford and more. We are dedicated to enabling advances in biomedical research and practice with AI and NLP.
We are creating a movement of people enthusiastically committed to a new vision for the future of biomedical research and we hope you want to join us.
Board Member
Aug 2022
rareLife partners with pharma and biotech companies for the successful development and commercialization of new therapies for rare diseases. Our offerings include customized rare disease solutions to improve all phases of product development.
Board Member
Jun 2021
Pregmune is revolutionizing fertility care by applying artificial intelligence, data science and reproductive immunology to identify often-overlooked causes of infertility.
Our introductory product, IRMA, is a comprehensive evaluation of blood markers and genetic traits found in scientific studies to contribute to implantation failure, miscarriage, or pregnancy complications.
Some tests (histocompatibility and chromosome analysis) involve both parents when a partner or sperm donor is available for testing. Additional tests check the patient for signs of an autoimmune condition or high inflammation levels, as well as assess the patient’s thyroid, metabolism, thrombophilia risk, nutrition status, and hormones.
The IRMA report includes a detailed analysis of test results, an AI-generated estimate of the likelihood that the patient and their partner or sperm donor will have a successful pregnancy while following our recommendations, and a personalized treatment plan.
IRMAs proprietary artificial intelligence model analyzes more than fifty different attributes including patient history, laboratory test results and patient demographics.
At Pregmune, we’re using science, technology and expertise to provide answers, recommend treatment, and help patients on their path to reproductive success.
Board Member
Jan 2021
Crisis24, a GardaWorld company, is widely regarded as the leading integrated risk management, crisis response, consulting, and global protective solutions firm, serving the worlds most influential people, disruptive brands, and prominent organizations. Championed by our advanced global operations centers and our highly skilled team of intelligence analysts, we offer highly specialized services, 24/7 security and consulting, with the technology and AI to power it across the globe.
Crisis24, une compagnie de GardaWorld, offre une expertise mondiale en gestion intégrée des risques de sécurité. Notre service du renseignement et nos solutions dintervention de crise et de solutions de protection globale permettent aux organisations, aux marques et aux personnes les plus influentes et innovatrices du monde de mener leurs activités en toute confiance. Sappuyant sur nos centres des opérations mondiales, sur le travail constant de notre équipe danalystes du renseignement et la puissante plateforme de gestion des risques de Crisis24, nous offrons des services de pointe, 24/7, à travers le monde.
Board Member
2014
The Aquaya Institute is a non-profit research and consulting organization. We deliver knowledge and tools to help achieve universal access to safe water.
Aquaya strengthens public and private delivery of clean water, sanitation, and hygiene (WASH) access in developing countries by combining cutting edge research with strategic consulting. Founded in 2005 by two PhD scientists, Aquaya’s goal is to bridge the divide between academic research and field implementation of measures that expand access to safe drinking water. We provide our clients and partners with in-depth knowledge and experience across a range of disciplines from water quality monitoring to consumer research to impact evaluation.
Experience · 9 entries
All (9)
Investments (5)
Founder (2)
Board (5)
2026
Board Member
Apr 2026
At Epistemic AI we are building the next generation of tools to accelerate biomedical research with AI and NLP.
We are a group of senior scientists and engineers from the likes of Google, New York University, Stanford and more. We are dedicated to enabling advances in biomedical research and practice with AI and NLP.
We are creating a movement of people enthusiastically committed to a new vision for the future of biomedical research and we hope you want to join us.
2022
Board Member
Aug 2022
rareLife partners with pharma and biotech companies for the successful development and commercialization of new therapies for rare diseases. Our offerings include customized rare disease solutions to improve all phases of product development.
2021
Board Member
Jun 2021
Pregmune is revolutionizing fertility care by applying artificial intelligence, data science and reproductive immunology to identify often-overlooked causes of infertility.
Our introductory product, IRMA, is a comprehensive evaluation of blood markers and genetic traits found in scientific studies to contribute to implantation failure, miscarriage, or pregnancy complications.
Some tests (histocompatibility and chromosome analysis) involve both parents when a partner or sperm donor is available for testing. Additional tests check the patient for signs of an autoimmune condition or high inflammation levels, as well as assess the patient’s thyroid, metabolism, thrombophilia risk, nutrition status, and hormones.
The IRMA report includes a detailed analysis of test results, an AI-generated estimate of the likelihood that the patient and their partner or sperm donor will have a successful pregnancy while following our recommendations, and a personalized treatment plan.
IRMAs proprietary artificial intelligence model analyzes more than fifty different attributes including patient history, laboratory test results and patient demographics.
At Pregmune, we’re using science, technology and expertise to provide answers, recommend treatment, and help patients on their path to reproductive success.
Board Member
Jan 2021
Crisis24, a GardaWorld company, is widely regarded as the leading integrated risk management, crisis response, consulting, and global protective solutions firm, serving the worlds most influential people, disruptive brands, and prominent organizations. Championed by our advanced global operations centers and our highly skilled team of intelligence analysts, we offer highly specialized services, 24/7 security and consulting, with the technology and AI to power it across the globe.
Crisis24, une compagnie de GardaWorld, offre une expertise mondiale en gestion intégrée des risques de sécurité. Notre service du renseignement et nos solutions dintervention de crise et de solutions de protection globale permettent aux organisations, aux marques et aux personnes les plus influentes et innovatrices du monde de mener leurs activités en toute confiance. Sappuyant sur nos centres des opérations mondiales, sur le travail constant de notre équipe danalystes du renseignement et la puissante plateforme de gestion des risques de Crisis24, nous offrons des services de pointe, 24/7, à travers le monde.
2015
Senior Advisor
Oct 2015
Chesky Partners is a boutique investment bank focused on strategic and transaction advisory services for leading healthcare and business services companies. We specialize in helping middle-market companies develop and achieve their strategic goals.
Strategic Advisory
We help companies evaluate their strategic alternatives and then formulate an execution plan. We have experience with a wide variety of strategic initiatives, both as advisors and as business operators.
Transaction (M&A) Advisory
We help clients execute strategic transactions, primarily mergers and acquisitions (M&A). We are experts at conducting competitive and disciplined M&A processes to maximize financial results for our clients.
Valuation & Fairness Opinion
We provide clients with reliable business valuations and fairness opinions, with a focus on the true “market value” of the company. In other words, we determine what a third-party would be willing to pay for the business.
Show all 9 entries ↓
Investment activity
2014–2026 · 5 investments
Recent (last 2 years)Earlier
